Immuneering announced that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research special conference targeting RAS, held March 5-8, 2023, in Philadelphia. The data shows response to IMM-1-104 across a diverse panel of RAS mutant preclinical models, regardless of mutation position or amino acid substitution, suggesting potential relevance to a broad RAS-driven patient population. The poster presentation at AACR special conference targeting RAS highlights the following preclinical data: Across all RAS-mutant models tested, at least one model displayed response to IMM-1-104 for each observed RAS mutation, regardless of mutation position or amino acid substitution; No significant preference was observed with respect to response to IMM-1-104 across 30 KRAS G12 mutated cell lines, the most commonly mutated position in KRAS, from three major cancer indications including pancreatic, lung and colorectal cancer models.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMRX:
- Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering To Present at Guggenheim 2023 Oncology Conference